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Abstract: About half of advanced stage head and neck squamous cell carcinoma (HNSCC) patients
can be cured by chemoradiotherapy. Patient outcome may be partially determined by the genetic
alterations in HNSCC, rendering these alterations promising candidate prognostic factors and/or
therapeutic targets. However, their relevance in patient outcome prognosis remains to be assessed
in patients that receive standard-of-care chemoradiotherapy. We therefore tested whether frequent
genetic alterations were associated with progression free survival (PFS) in advanced stage HNSCC
patients who were uniformly treated with definitive platinum-based chemoradiotherapy. To this
end, we performed targeted DNA sequencing on frozen pre-treatment tumor biopsy material from
77 patients with advanced stage oro- and hypopharyngeal carcinoma. This provided somatic point
mutation and copy number aberration data of 556 genes. The most frequently mutated genes, TP53
(62%), CCND1 (51%), CDKN2A (30%) and PIK3CA (21%), were not associated with PFS. However,
co-occurring CCND1 and CDKN2A mutations were associated with short PFS (HR 2.24, p = 0.028)
in HPV-negative tumors. Furthermore, tumor mutational burden (sum of somatic point mutations)
showed a trend towards decreased PFS (HR 1.9, p = 0.089), and chromosomal instability (CIN)
was associated with shorter PFS (HR 2.3, p = 0.023), independent of HPV status. Our results show
that tumor mutational burden, CIN markers, and co-occurring CCND1 and CDKN2A mutations
are associated with chemoradiotherapy outcomes in advanced stage oro- and hypopharyngeal
HNSCC patients, thereby highlighting their prognostic potential. Given their poor prognosis
association and link to biological targets, they may also identify patients for novel targeted therapies
and immunotherapies.
Keywords: head and neck squamous cell carcinoma; pharyngeal neoplasms; genomics; DNA
sequence analysis; mutation; chemoradiotherapy; prognosis
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1. Introduction
Advanced stage head and neck squamous cell carcinoma (HNSCC) has a poor prognosis.
Chemoradiotherapy cures about half of all patients with advanced HNSCC. Allowing the preservation
of organ function, it has become the preferred treatment option for these cancers [1]. Patients with
a poor prognosis under such standard treatment may be eligible for increased surveillance and/or
alternative treatments if they could be identified upfront. However, the current TNM staging [2] based
prognosis is very limited in this regard and novel prognostic biomarkers are therefore urgently needed.
Tumor growth and treatment responses are largely determined by tumor intrinsic genetics.
Genomic features therefore hold the promise of providing potential treatment response biomarkers.
Frequent alterations are of particular interest for this purpose. Previous studies identified
commonly mutated genes through large comprehensive DNA sequencing efforts and genetic analyses,
thereby revealing the “driver genes” in HNSCC [3–5]. Their prognostic value is currently under
investigation [6–12]. Pairs of co-occurring mutated genes can also hold prognostic information [13],
and this can point to a functional link between the events. This can also apply across different types of
genetic features in tumors; e.g., mutations in mismatch repair genes are linked to a high mutational
burden [14] and homologous recombination repair gene mutations to overall gene copy number
alterations (CNAs) [15].
DNA crosslink repair defect analyses in a large panel of patient-derived HNSCC cell lines
revealed that HNSCC are frequently characterized by DNA repair (DR) defects [16]. Potentially
disrupting mutations were found in multiple genes of this pathway in both patient tumors and cell
lines. We also found that such mutations are associated with a poor outcome in HNSCC patients
treated with chemoradiotherapy [16]. While DR provides cellular drug and radiation resistance
through repair, it also governs genomic stability. Defects in DNA repair thus promote genomic
instability, thereby enabling cancer cells to acquire new genetic traits, including those necessary to
become therapy resistant. Indeed, the degree of a tumor’s genomic instability or DNA repair status
is associated with poor prognosis in cancer and can therefore be of prognostic value [17,18]. In a
previous study we showed that genomic instability measures vary between tumors of the oral cavity,
larynx, and pharynx [15]. Measurements of genomic instability and correlates of DNA repair defects
vary, but markers thereof can be obtained with genomic profiling. The total number of somatic point
mutations (SPMs) in tumor DNA (“mutational burden”), alterations in ploidy, and/or the presence
of chromosomal alterations—gains or losses—termed chromosomal instability (CIN) are possible
markers of such factors [19].
Important questions, as to the prognostic value of the genomics in HNSCC, remain. Many
studies focused solely on individual alterations. Even though frequent in HNSCC [4,5], the joint
prognostic value of SPMs and CNAs in HNSCC has also not been assessed yet. In addition, previously
studied cohorts often comprised tumors of various HNSCC sites. Patients were treated dissimilarly
with a bias towards surgical resection of the tumor in most studies. However, HNSCC tumors from
different anatomic sites have distinct genomic profiles [15]. Consequently, it remains to be determined
which genetic markers are prognostic in specific sites treated with a uniform and contemporary
modality. Importantly, since the large TCGA HNSCC study incorporated solely samples from resected
HNSCC and included mostly oral cavity tumor specimens, oro- and hypopharyngeal carcinoma
patients treated with standard-of-care definitive chemoradiotherapy are either not included or largely
underrepresented in most current studies.
We therefore aimed to identify prognostic genetic factors of advanced stage pharyngeal squamous
cell carcinoma treated with chemoradiotherapy. We performed a retrospective study based on
pre-treatment tumor biopsies from 77 advanced stage HNSCC patients that all received cisplatin-based
chemoradiation. Targeted DNA sequencing of these tumor biopsies was performed to identify gene
mutations, and SPMs and CNAs were determined. These data were used to address the following
questions: Are (1) mutated genes or co-occurring mutated genes, (2) mutational burden and/or (3) CIN
markers associated with progression free survival (PFS)?
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2. Results
2.1. Patient Characteristics and Sequencing
In order to assess the potential prognostic value of frequent genetic factors, we genetically
characterized 77 oro- and hypopharyngeal carcinoma samples (patient characteristics shown in Table 1).
The median PFS in this cohort was 5.8 years (95% CI: 4.5–8.9). As reported previously in similar
patient cohorts, PFS was significantly linked to tumor site and HPV status (Table 1, Supplementary
Materials: Figure S1 and Table S1). Tumor site and HPV status were therefore consistently included
as independent variables in multivariable Cox models when testing for associations between genetic
factors and PFS. Non-silent SPMs and CNAs were determined on targeted sequencing data of 556 genes
(Supplementary Materials: Table S2) to identify gene mutations, deletions, and amplifications. In total,
416 non-silent SPMs were found in the sequenced genes, comprising mostly missense mutations (~80%,
Supplementary Materials: Table S3).
In addition to individual gene mutations, we used the sum of all SPMs (including silent) in
all sequenced genes in a tumor sample as a measure of its overall mutational burden. The median
mutational burden was 5 per sample or 2.8 mutations per Mb (Supplementary Materials: Figure S2),
a value comparable to previous findings by whole exome sequencing in HNSCC [20]. CNA analyses
on all targeted and sequenced genes provided ploidy estimates that served as a CIN marker. A total
of 42% of the samples were classified as CIN+ according to this analysis. Together, our HNSCC data
confirmed the mutational burden and chromosomal instability rich features that are characteristic to
pharyngeal HNSCC [15].
Table 1. Patient and tumor characteristics. Follow-up and progression free survival (PFS) times in years.
Variable
All Patients HPV-Negative HPV-Positive
p-ValueN = 77 N = 56 N = 21
N (%) N (%) N (%)
Gender
Male 22 (29) 17 (30) 5 (24) 0.778
Female 55 (71) 39 (70) 16 (76)
Tumor site
Hypopharynx 28 (36) 28 (50) 0 (0) <0.001
Oropharynx 49 (64) 28 (50) 21 (100)
Disease stage
III 11 (14) 9 (16) 2 (10) 0.717
IV 66 (86) 47 (84) 19 (90)
cT classification
T1-T3 49 (64) 33 (59) 16 (76) 0.192
T4 28 (36) 23 (41) 5 (24)
cN classification
N0-N2a 24 (31) 20 (36) 4 (19) 0.181
N2b-N3 53 (69) 36 (64) 17 (81)
Smoker
Former 20 (26) 12 (21) 8 (38) <0.001
Never 7 (9) 1 (2) 6 (29)
Unknown 2 (3) 2 (4) 0 (0)
Yes 48 (62) 41 (73) 7 (33)
Alcoholic consumption
Former alcoholic 13 (17) 13 (23) 0 (0) 0.005
Never 10 (13) 4 (7) 6 (29)
Unknown 2 (3) 2 (4) 0 (0)
Yes 52 (68) 37 (66) 15 (71)
Median age at diagnosis (range) 58 (27–78) 58.5 (37–78) 57 (27–77) 0.175
Median follow-up (95% CI) 8.2 (6.7–10.5) 9.3 (7.8–NA) 6.6 (5.9–10.2) 0.113
Number of PFS events (%) 47 (61) 43 (77) 4 (19) <0.001
Median PFS (95% CI) 5.8 (4.5–8.9) 4.5 (1.8–6.2) NA <0.001
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2.2. “HNSCC Driver Genes”
First, we aimed to investigate the association of known “HNSCC driver genes”, as determined by
Iorio et al. and based on SPM and CNA data [4], with PFS (see Methods and Supplementary Materials:
Tables S4 and S5). For these PFS association analyses and consistent with the Iorio et al. identification
criteria, only the genetic alteration type by which a gene was originally detected as a potential driver
was considered [4]. For example, CDKN2A was identified as a potential HNSCC driver gene by its
frequent presence of SPMs and deletions but not by amplifications. Amplifications were therefore
not considered for CDKN2A sample classification, but SPMs and deletions were. The PFS association
analyses were further restricted to frequently mutated genes only, a valuable requirement for any
potential prognostic factor. In this study we therefore restricted the analyses to those genes which
were mutated in the tumors of at least 10 patients, as this also allowed us to adequately fit a regression
model [21,22]. Of all genes, the tumor suppressor gene TP53, the cell cycle regulators CCND1 and
CDKN2A, and the growth signaling gene PIK3CA met these criteria (Table 2). Notably, CCND1 and
CDKN2A alterations were only found in the HPV-negative tumor samples. We then used multivariable
Cox models (with HPV and tumor site, see above) to investigate whether mutations in these genes
were associated with PFS. Only in the CCND1 analyses we found a trend towards shorter PFS for
carriers of tumors with such amplifications (Table 2 and Supplementary Materials: Figure S3). This was
the case regardless of whether HPV-positive samples were included or not (Table 2 and Figure 1A,B).
We next investigated pairs of co-occurring mutated genes. Tumors were classified as positive,
in which both genes were mutated, and the rest as negative. Three pairs of co-occurring mutated
genes were tested after applying the same restriction as above, of minimal 10 patients for each
classification (Table S6). We found that patients with tumors harboring co-occurring CCND1
mutations (amplifications) and CDKN2A mutations (SPMs and deletions) had shorter PFS than the rest
(multivariable Cox: HR 2.24, 95% CI: 1.09–4.61, p = 0.028) (Supplementary Materials: Figure S3C).
In HPV-positive tumors, no mutations were detected in the cell cycle regulators CCND1 or
CDKN2A. This is consistent with the lack of a requirement for such mutations since the HPV viral
protein E7 affects cell cycle regulation. Importantly, the prognostic significance of co-occurring CCND1
and CDKN2A mutations remained even after excluding HPV-positive tumors (multivariable Cox:
p = 0.029, Figure 1C).
Taken together, we tested recurrently mutated “HNSCC driver genes” for an association with
PFS. Although none of the individual genes reached significance, the co-occurrence of CCND1 and
CDKN2A mutations was associated with shorter PFS in our patient dataset.
Table 2. Prevalence of selected driver gene mutations and association with progression free
survival (PFS).
Gene Mutation a
Prevalence Survival Analysis b
All
Patients
HPV-
Negative
HPV-
Positive
p-Value
PFS
N = 77 N = 56 N = 21
N (%) N (%) N (%) HR p-Value
TP53 SPM 48 (62) 47 (84) 1 (5) <0.001 0.87 0.753
CCND1 A 39 (51) 39 (70) 0 (0) <0.001 2.1 0.079
CDKN2A SPM or D 23 (30) 23 (41) 0 (0) <0.001 1.17 0.663
PIK3CA SPM 16 (21) 10 (18) 6 (29) 0.35 1.16 0.732
a SPM = Somatic Point Mutation, A = Amplification, D = Deletion. b Multivariable Cox model with the additional
independent variables HPV status and tumor site.
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Figure 1. Progression free survival (PFS) according to genetic alterations in CCND1 and CDKN2A. 
Kaplan–Meier curves of advanced stage pharyngeal HNSCC patients classified according to tumor 
CCND1 and CDKN2A status: (A) CCND1 amplification versus wildtype. (B) CDKN2A mutation or 
deletion versus wildtype. (C) CCND1 amplification co-occurring with CDKN2A mutation or deletion, 
versus wildtype for one or either of these two genes. In-figure legends of A–B state hazard ratios (HR) 
and corresponding p-values from multivariable Cox models that were fitted on all (n = 77) samples 
and included the tested genetic factor, HPV status, and tumor site. In-figure legend of C states the 
hazard ratio (HR) and corresponding p-value from a multivariable Cox model that was fitted on these 
HPV-negative samples only (n = 56) and included the tested genetic factor and tumor site. Note, all 
graphs display Kaplan–Meier curves of HPV-negative samples only (n = 56) with the corresponding 
log–rank test. 
2.3. CCND1 and CDKN2A Expression and Patient Outcome 
Of the 15 tumors that carried co-occurring CCND1 and CDKN2A mutations, all carried a CCND1 
amplification, 1/15 had a CDKN2A frameshift SPM, and 14/15 a CDKN2A deletion. Gene copy number 
aberrations were thus the primary gene alteration in this HNSCC subgroup that displayed 
significantly shorter PFS. We reasoned that these CNAs might be reflected in RNA expression 
changes which could therefore be used as a prognostic biomarker. To test whether this was feasible, 
we analyzed RNA-seq data available for 74 of the 77 tumors. Indeed, we found that CDKN2A deletion 
was associated with low CDKN2A expression (p < 0.001) and CCND1 amplification with high CCND1 
expression (p < 0.001) (Figures 2A–C). However, CCND1 and CDKN2A expression could not 
accurately discriminate tumors with co-occurring CCND1 amplifications and CDKN2A deletions 
(Figure 2C). 
We then classified tumors into low and high expression groups using the median expression as 
the threshold value. High CCND1 expression and CDKN2A expression showed an association with 
poor prognosis in univariate models based on all samples (log–rank p = 0.032 and p = 0.01, 
respectively). However, this was due to HPV-positive tumors and hence lost in the multivariable 
analyses (Figure 2D,E). Tested as a numeric (continuous) variable, as opposed to the median split, 
expression was not significantly associated with PFS either (data not shown). A co-occurrence 
analysis based on the median expression classifications did not reveal an association with PFS either 
(Figure 2F).  
Taken together, the prognostic value of CCND1 and CDKN2A was evident in the gene 
mutational analysis but not in the expression analyses. In fact, RNA expression analyses were unable 
to discriminate between CDKN2A wildtype and deleted CDKN2A in the HPV-negative samples 
(Figure 2B). At this stage, it is difficult to assess whether this may be a consequence of technical 
sensitivity issues due to stromal contamination. 
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Figure 1. Progression free survival (PFS) according to genetic alterations in CCND1 and CDKN2A.
Kaplan–Meier curves of advanced stage pharyngeal HNSCC patients classified according to tumor
CCND1 and CDKN2A status: (A) CCND1 amplification versus wildtype. (B) CDKN2A mutation or
deletion versus wildtype. (C) CCND1 amplification co-occurring with CDKN2A mutation or deletion,
versus wildtype for one or either of these two genes. In-figure legends of A–B state hazard ratios (HR)
and corresponding p-values from multivariable Cox models that were fitted on all (n = 77) samples
and included the tested genetic factor, HPV status, and tumor site. In-figure legend of C states the
hazard ratio (HR) and corresponding p-value from a multivariable Cox model that was fitted on these
HPV-negative samples only (n = 56) and included the tested genetic factor and tumor site. Note, all
graphs display Kaplan–Meier curves of HPV-negative samples only (n = 56) with the corresponding
log–rank test.
2.3. CCND1 and CDKN2A Expression and Patient Outcome
Of the 15 tumors that carried co-occurring CCND1 and CDKN2A mutations, all carried a CCND1
amplification, 1/15 had a CDKN2A frameshift SPM, and 14/15 a CDKN2A deletion. Gene copy number
aberrations were thus the primary gene alteration in this HNSCC subgroup that displayed significantly
shorter PFS. We reasoned that these CNAs might be reflected in RNA expression changes which could
therefore be used as a prognostic biomarker. To test whether this was feasible, we analyzed RNA-seq
data available for 74 of the 77 tumors. Indeed, we found that CDKN2A deletion was associated with
low CDKN2A expression (p < 0.001) and CCND1 amplification with high CCND1 expression (p < 0.001)
(Figure 2A–C). However, CCND1 and CDKN2A expression could not accurately discriminate tumors
with co-occurring CCND1 amplifications and CDKN2A deletions (Figure 2C).
We then classified tumors into low and high expression groups using the median expression
as the threshold value. High CCND1 expression and CDKN2A expression showed an association
with poor prognosis in univariate models based on all samples (log–rank p = 0.032 and p = 0.01,
respectively). However, this was due to HPV-positive tumors and hence lost in the multivariable
analyses (Figure 2D,E). Tested as a numeric (continuous) variable, as opposed to the median split,
expression was not significantly associated with PFS either (data not shown). A co-occurrence analysis
based on the median expression classifications did not reveal an association with PFS either (Figure 2F).
Taken together, the prognostic value of CCND1 and CDKN2A was evident in the gene mutational
analysis but not in the expression analyses. In fact, RNA expression analyses were unable to
discriminate between CDKN2A wildtype and deleted CDKN2A in the HPV-negative samples
(Figure 2B). At this stage, it is difficult to assess whether this may be a consequence of technical
sensitivity issues due to stromal contamination.
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Figure 2. CCND1 and CDKN2A expression and patient outcome. (A) CCND1 expression in tumors with
(‘ampl’) and without (‘wt’) CCND1 amplification. (B) CDKN2A expression in tumors with (‘del) and
without (‘wt’) CDKN2A deletion. (C) CDKN2A against CCND1 expression per tumor sample, colored
according to the presence (filled circles) or absence (open circles) of a co-occurring CCND1 amplification
and CDKN2A deletion. Dashed lines demarcate the median expression, according to which the samples
received a high or low expression classification in D–F. (D–F) Kaplan–Meier curves of progression
free survival (PFS) according to CCND1 and CDKN2A expression status. Dashed lines represent all
samples; solid lines represent HPV-negative samples only. Note, orange lines overlap in E–F. In-figure
legends in D–F state hazard ratios (HR) and corresponding p-values from multivariable Cox models
that were fitted on all (n = 77) samples and included the tested genetic factor, HPV status, and tumor
site. In-figure stated log–rank tests correspond to the analyses in HPV-negative samples only.
2.4. Mutational Burden and CIN
We next aimed to investigate the prognostic value of genomic instability and DR defect related
markers, as these are common in HNSCC [15]. Limited by the lack of whole exome or genome
sequencing data, we used the estimates of mutational burden and CIN determined by ploidy estimates
as described in the Materials and Methods Section. We find that in comparison to HPV-positive tumors,
HPV-negative tumors had a higher mutational burden (p = 0.006) and were more often classified as
CIN+ (p < 0.001) (Table 3).
We then tested whether mutational burden and CIN were associated with PFS using multivariable
Cox models. When divided into “high” and “low mutational burden” groups according to the median
mutational burden value, patients with a high tumor mutational burden had a trend towards shorter
PFS (multivariable Cox with tumor site and HPV: HR 1.87, 95% CI: 0.91–3.86, p = 0.089) (Figure 3A
and Table 3). CIN was associated with PFS as patients with CIN+ tumors had shorter PFS than those
without (multivariable Cox: HR 2.3, 95% CI: 1.12–4.71, p = 0.023) (Figure 3B and Table 3).
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Table 3. The association of mutational burden (total number of somatic point mutations) and presence
of the chromosomal instability marker (CIN) with progression free survival (PFS).
Variable
Prevalence Survival Analysis c
All Patients HPV-Negative HPV-Positive
p-Value PFSN = 77 N = 56 N = 21
N (%) N (%) N (%) HR p-Value
Mutational burden a
Per tumor 5 (0–16) 5 (1–14) 2 (0–16) 0.006 1.08 0.197
Mutational burden groups b
High 31 (40) 26 (46) 5 (24) 0.116 1.87 0.089
Low 46 (60) 30 (54) 16 (76)
CIN b
Positive 32 (42) 30 (54) 2 (10) <0.001 2.3 0.023
Negative 45 (58) 26 (46) 19 (90)
a Reports the median, range, and Wilcoxon rank–sum test p-value. b Reports the absolute number of tumors,
percentage, and Fisher’s exact test p-value. c Multivariable Cox model with HPV status and tumor site as additional
independent variables.
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Figure 3. Progression Free Survival (PFS) according to mutational burden and chromosomal instability.
Kaplan–Meier curves of PFS after patient classification by the following genomic factors in their tumors:
(A) High or low utational burden, (B) presence (CIN+) or absence (CIN-) of chromosomal instability
markers (CIN) and (C) mutational burden and CIN. In-figure lege ds state hazard ratios (HR) and
p-values from multivari ble Cox models that included the tested ge omic factor, HPV status, and
tumor site. The HR shown in (C) refers to patients that have tumors with a high mutational burden
and that show presence of CIN in their tumors, compared to those with a low mutational burden and
absence of CIN.
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Although CIN+ tumors had a “high mutational burden” classification more often than tumors
without CIN (56% versus 29%, p = 0.02), this did not always co-occur. Importantly, when included
into the same multivariable model, with tumor site and HPV status as co-variables, CIN remained
significant, and mutational burden showed a trend (p = 0.019 and p = 0.07, respectively). In this model,
both CIN+ (HR 2.35, 95% CI: 1.15–4.81) and high mutational burden (HR 1.91, 95% CI: 0.95–3.86) were
associated with shorter PFS. Importantly, it was the patients with tumors classified by both genetic
features, a CIN+ and a high mutational burden, who had the shortest PFS (multivariable Cox: HR 3.63,
95% CI: 1.41–9.31, p = 0.007) (Figure 3C).
Next, we combined all three prognostic genetic factors to assess whether they were independent
predictors of PFS. We first tested for possible associations of co-occurring CCND1 and CDKN2A
mutations with mutational burden and CIN in the samples and found those alterations to be more
prevalent in the HPV-negative samples (Supplementary Materials: Figure S4). Given the association of
these genetic alterations with each other and with HPV status (Supplementary Materials: Figure S4),
it is worthwhile to assess their independent prognostic value in a multivariable analysis. In fact, the
association of high mutational burden and CIN with short PFS remained as a trend in multivariable
Cox models that combined mutational burden, CIN, co-occurring CCND1 and CDKN2A mutations,
tumor site, and HPV status (with p = 0.079 and p = 0.059, respectively).
Taken together, we found that the presence of CIN was associated with short PFS in our cohort
(in an HPV-status independent manner). Furthermore, the combined presence of CIN and a high
mutational burden marked patients with a particular poor prognosis.
3. Discussion
We found that a high mutational burden showed a trend towards poor prognosis and that
CIN/aneuploidy was associated with short PFS in our cohort of advanced stage oro- and hypopharynx
carcinoma patients treated with chemoradiotherapy. A high mutational burden has been linked to poor
prognosis in surgically resected HNSCC [8] and other cancer types [13,23]. Similarly, the association
between CIN and poor prognosis has been demonstrated in various cancer types [24–26], including
surgically resected HNSCC [27]. Mutant-allele tumor heterogeneity (MATH), a mutation-based
measure of genetic heterogeneity, was found to be associated with poor prognosis in resected
HNSCC [28]. Our findings thus confirm this poor prognostic pattern also for HNSCC patients
who received chemoradiotherapy. They suggest that mutational burden and CIN are potential
biomarkers in advanced stage HNSCC treated with chemoradiotherapy. DNA repair defects can cause
genomic instability [29,30] and can therefore correlate with measurements thereof, such as mutational
burden or CIN. Our results are therefore consistent with our previous reports demonstrating the
presence of DNA repair defects in HNSCC and its association with poor prognosis [16]. Although
therapeutic exploitation of CIN is currently not feasible in the clinic, strategies to do so are under
investigation [31,32]. Tumor DNA repair defects on the other hand can be exploited by the use of DNA
repair inhibitors [33].
The mutation frequencies in the “HNSCC driver genes”, defined by Iorio et al., that were observed
in our study are consistent with similar HNSCC reports [3,8,10,11,34]. However, not all “HNSCC
driver genes” [3,4] were sequenced in this patient cohort. The prognostic value of the remaining
genes still needs to be determined for patients treated with chemoradiotherapy in future research.
Individually, none of the mutated genes that were analyzed was associated with PFS in our cohort.
This was despite, or because of, stringent statistical requirements for analysis (minimum of 10 patients
per group). An improved outcome of patients with NOTCH1-mutated tumors was reported in a similar
cohort [11]. Due to the limitation in cohort size, this finding was based on two events (deaths) in
12 patients with NOTCH1-mutated tumors. NOTCH1 was part of our target genes but did not meet
the frequency criteria in our cohort. Yet, when testing this reported association in our cohort, we did
not observe an association between NOTCH1 mutations status and PFS (data not shown). It should
be noted, however, that a low patient and/or event number impedes strong conclusions from low
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prevalence mutations outcome association analyses in the medium-sized cohorts that are available,
including ours [21,22]. Yet, our cohort had similar clinical and genetic features as comparable cohorts.
Indeed, to mitigate the uncertainty caused by the sample size, we only tested associations with those
mutated genes that were present in at least 10 patients with a PFS event.
Furthermore, poor outcome of patients with TP53-mutated tumors has been reported in multiple
studies [8,10,11], even after correcting for HPV-status. However, each of these studies selected a
different subset of TP53 SPMs, as identified by different algorithms aimed at discriminating harmful
from benign TP53 SPMs. This difference in the classification of TP53 mutations hampers comparison
between studies. One should also note that it remains uncertain whether HPV-negative tumors
classified as TP53-wildtype are truly TP53-wildtype as multi-codon deletions are difficult to detect
with short-read sequencing technologies.
The discrepancies between studies underscore the challenges of HNSCC prognostic biomarker
research that lag behind those of other cancer types [13,35]. Owing to a high heterogeneity of the
disease, it is difficult to obtain large cohorts of patients treated with the same modality and with
homogenous tumors (in terms of stage and site). Comparing oral with pharyngeal HNSCC, our
previous study [15] pointed to the presence of discrete genomic features in each site. Patient outcome
parameters will be also largely affected by the different treatment options in a tumor biology and
genomics dependent manner, and this highlights the need for treatment uniformity in such cohorts.
We therefore opted for a homogenous cohort of patients to assess the impact of frequent HNSCC
gene mutations.
The association of co-occurring CCND1 and CDKN2A mutations with short PFS is remarkable,
given the similar role in cellular biology. The protein product of CCND1, cyclin D1, forms a complex
with cyclin-dependent kinases (CDKs) CDK4 or CDK6. This complex promotes cell cycle progression
through the G1/S checkpoint but can be inhibited by the protein product of CDKN2A, p16. As either
CCND1 amplification or CDKN2A loss could promote cell cycle progression, these mutations seem
redundant at first sight [36]. The high prevalence of co-occurring CCND1 and CDKN2A mutations
in HNSCC does however suggest an additional growth advantage [36,37] and is supported by our
findings and in vitro and in vivo data of others [38,39]. Supported by immunohistochemistry, FISH or
RT–PCR, four earlier studies reported that the co-occurrence of CCND1 overexpression or gain and the
CDKN2A loss of expression, under-expression, or deletion marks a specific group in HNSCC with poor
prognosis [40–43]. This is consistent with our findings based on gene mutation analyses. The deletion
of CDKN2A may influence the interaction opportunity of survivin with CDK4 and further supports
cell proliferation driven by the cyclin D amplification [44]. Survivin also suppresses apoptosis and its
overexpession has been shown to be associated with poor prognosis in surgically resected HNSCC
and OSCC [45,46].
Strong genetic biomarkers can guide clinical decision-making in the future. Patients with a
confirmed poor prognosis may be eligible for a different, intensified, or targeted treatment and/or may
benefit from increased surveillance. Genetic biomarkers can also provide clues for such alternative
treatments and administration of targeted agents. CCND1 overexpression due to amplification and its
cellular activity or loss of CDKN2A is for example targetable with CDK4/6 inhibitors [4,47,48]. One
such inhibitor, palbociclib, is currently being tested for HNSCC [49].
4. Materials and Methods
4.1. Patients
Pretreatment HNSCC samples were collected by biopsy and fresh frozen for biobanking; they
were available for retrospective analyses. All patients gave their informed consent. The study
was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics
Committee, the Institutional Review Board of the Netherlands Cancer Institute (P05MD1). Samples
were obtained from 77 patients with oro- and hypopharyngeal carcinoma and treated with cisplatin
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based chemoradiotherapy at our institute between 2001 and 2010. Biopsy material with at least 50%
tumor cells, as determined on H&E (haematoxylin and eosin stained) sections, was processed for
DNA extraction. Matched normal samples were unavailable for the majority of tumors, and genomic
analyses were therefore performed on tumor samples only. Patient cohort and tumor characteristics
are described in Table 1.
4.2. Sequencing and Bioinformatics Protocol
Details of the DNA and RNA sequencing and bioinformatics protocols are specified in the
Supplementary Methods [50–59]. In short, we performed target capture DNA sequencing of 556 human
genes (Supplementary Materials: Table S2). HPV gene baits, to capture HPV DNA in the samples,
were included in order to determine HPV status. We removed DNA sequence variants that were in
any of three public SNP databases [54–56] and classified the remaining non-silent variants as SPMs.
Homozygous deletions and focal amplifications were detected using the R package PureCN [57]. We
used PureCN’s ploidy estimates as a chromosomal instability (CIN) marker. These estimates were
rounded to the nearest integer and values not equaling 2 were classified as CIN+ (presence of CIN).
4.3. “HNSCC Driver Genes”
We used the “HNSCC driver genes” published by Iorio et al. that were identified by a large
cohort of HNSCC. All HNSCC patients in this study underwent surgical resection and thus were not
treated with definitive chemoradiotherapy [4]. A total of 168 “HNSCC driver genes” were identified
by algorithms that select genes with more non-silent SPMs than expected by chance given various
background mutation rates and processes (Supplementary Materials: Table S4). An additional 25 genes
were selected from 33 regions identified as “drivers” by Iorio et al., by an analysis that selects regions
with recurrent CNAs (Supplementary Materials: Table S5). We selected all genes that reside within
these regions and that were annotated in the Cancer Gene Census [60] (Supplementary Materials:
Table S5). A total of 27 out of the 168 SPM affected genes and 11 out of the 25 genes with recurrent
CNAs (Supplementary Materials: Tables S4 and S5) were captured in our targeted sequencing panel
(Supplementary Materials: Table S2). These amounted to 35 unique “HNSCC driver genes”, as three
genes (CDKN2A, EGFR, and NOTCH1) were identified by both SPMs and CNAs.
4.4. Statistical Methods
Categorical and numerical variables were compared between groups with Fisher’s exact test
and the Wilcoxon rank–sum test, respectively. Median follow-up time was derived from a reverse
Kaplan–Meier analysis [61]. Except for in-figure log–rank test p-values, all reported survival analyses
were obtained with multivariable Cox proportional hazards models that were used to test for
associations between the selected genomic factors and PFS. Each model included the genomic
factor, HPV status, and tumor site. HPV status and tumor site were included since they are
strong prognostic factors in advanced HNSCC and were also prognostic in our cohort (Table 1 and
Supplementary Materials: Table S1). All statistical analyses were performed in the R environment for
statistical computing.
5. Conclusions
Our study shows that mutational burden estimates, CIN/aneuploidy markers, and co-occurring
CCND1 and CDKN2A mutations in advanced stage oro- and hypopharyngeal HNSCC are associated
with patient outcomes. This highlights their potential as prognostic factors in advanced stage
HNSCC patients treated with chemoradiotherapy and may have implications for targeted therapies
or immunotherapies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/4/445/s1:
Figure S1. Progression free survival (PFS) stratified by HPV status and tumor site; Figure S2. Tumor mutational
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burden; Figure S3. Progression free survival (PFS) according to genetic alterations in TP53, PIK3CA, CCND1, and
CDKN2A; Figure S4. Mutational burden and chromosomal instability features in samples according to CCND1
and CDKN2A mutation co-occurrence; Table S1. Patient and tumor characteristics of HPV-negative tumor samples,
stratified by tumor site; Table S2. List of targeted genes in DNA sequencing capture set; Table S3. Classification of
the identified somatic point mutations; Table S4. List of "HNSCC driver genes"; Table S5. List of "HNSCC driver
regions"; Table S6. Frequency table of co-occurring gene mutations, Supplementary Methods.
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